Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06773871

Feasibility and Safety of Exercise in Patients With Low-risk Myeloid Cancers and Precursor Conditions

Led by Rigshospitalet, Denmark · Updated on 2025-08-19

36

Participants Needed

2

Research Sites

94 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Somatic mutations as seen in myeloid malignancies can also be detected in healthy, elderly individuals (clonal hematopoiesis of indeterminate potential, CHIP), in patients with unex-plained cytopenia, that do not fulfill the criteria for myeloid malignancy (clonal cytopenia of un-determined significance, CCUS) It has been shown that these conditions predispose to hema-tological cancer. For patients with CCUS, it has been reported that in a 5-year period up to 50-90 % of the patients will progress to myelodysplastic syndrome (MDS) or acute myeloid leu-kemia (AML), both devastating diseases with poor outcomes, especially for the elderly popula-tion. There is currently no treatment available for patients with CCUS besides supporting agents. Since the somatic mutations can be detected up to 10 years before a diagnosis of MDS, it opens the potential for early intervention. Physical inactivity is associated with multiple solid cancers, and it has been suggested that exercise can prevent for example certain colon- or breast cancers. Studies in mice have shown that exercise can reduce tumor size and incidence of solid cancers, and different mechanisms have been suggested including increased immune cell infiltration, reduced systemic inflamma-tion, and metabolic changes. The mechanisms of disease progression of pre-leukemia and MDS are complex and probably multifactorial, but recent studies suggest that components such as natural killer cells, adipocytes, and inflammatory substances in the bone marrow mi-croenvironment play a crucial role; factors that exercise may modulate. In addition, recent stud-ies have shown that increased bone marrow adipose tissue (BMAT) may create a microenvi-ronment that supports the expansion of leukemic cells and thus may facilitate disease progres-sion, and earlier studies among healthy, younger individuals have shown that exercise can reduce the amount of BMAT significantly. Therefore, the investigators hypothesize that exercise may prevent or delay the progression from pre-leukemia to leukemia by altering the microenvironment in the bone marrow. The purpose with this clinical, pilot trial where patients with the preleukemic condition CCUS or early stage of leukemia (i.e., lower-risk MDS) will undergo an individualized exercise interven-tion, is to investigate: 1. whether an exercise intervention and the trial set-up, are feasible and safe in this cohort, 2. potential mechanisms in leukemogenesis affected by exercise in controlling dis-ease progression, 3. and the effect hereof on quality of life and activities of daily living. The above will inform the decision-making on designing a larger randomized, controlled trial.

CONDITIONS

Official Title

Feasibility and Safety of Exercise in Patients With Low-risk Myeloid Cancers and Precursor Conditions

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of lower-risk myelodysplastic syndrome or clonal cytopenia of undetermined significance (WHO 2022 Classification)
  • Age over 18 years
  • Performance status less than or equal to 2
  • Written informed consent before study procedures
Not Eligible

You will not qualify if you...

  • Physically unable to participate in exercise (e.g., due to arthrosis or physical disabilities)
  • Regular exercise practice above low level according to IPAQ-SF screening
  • Unwilling to participate in exercise intervention
  • Current use of metformin
  • Treatment with chemotherapy, radiation, or immunosuppressive therapy within the last year
  • Treatment with hypomethylating agents
  • Any absolute contraindication to cardiopulmonary exercise testing per American Heart Association and Danish Society of Cardiology guidelines
  • Hemoglobin below 5.5 mmol or below 6.5 mmol with cardiac insufficiency or pacemaker
  • Blood transfusion dependence of 8 or more units in 16 weeks
  • Uncontrolled co-morbid conditions

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Rigshospitalet

Copenhagen, Denmark, Denmark, 2100

Not Yet Recruiting

2

Rigshospitalet

Copenhagen, Denmark

Actively Recruiting

Loading map...

Research Team

K

Kirsten Gørnbæk, Professor

CONTACT

S

Stine Bitsch-Olsen, MSc

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here